Personalized Dose of Adjuvant Imatinib in Patients with Gastrointestinal Stromal Tumors: Results from a Population Pharmacokinetic Analysis

PURPOSE: Imatinib is the first-line treatment for patients with gastrointestinal stromal tumors (GIST) after surgery. However, its pharmacokinetic profile varies remarkably between individuals and has not been well characterized in postoperative Chinese patients with GIST. Therefore, this study aime...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Xuehui, Fu, Qun, Jing, Yan, Kong, Ying, Liu, Hong, Peng, Hongwei, Rexiti, Kaisaner, Wei, Xiaohua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024496/
https://www.ncbi.nlm.nih.gov/pubmed/36942304
http://dx.doi.org/10.2147/DDDT.S400986

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024496/
https://www.ncbi.nlm.nih.gov/pubmed/36942304
http://dx.doi.org/10.2147/DDDT.S400986

Ejemplares similares